全文获取类型
收费全文 | 36697篇 |
免费 | 2125篇 |
国内免费 | 108篇 |
专业分类
耳鼻咽喉 | 483篇 |
儿科学 | 970篇 |
妇产科学 | 792篇 |
基础医学 | 6829篇 |
口腔科学 | 684篇 |
临床医学 | 3297篇 |
内科学 | 7372篇 |
皮肤病学 | 970篇 |
神经病学 | 3162篇 |
特种医学 | 1853篇 |
外国民族医学 | 2篇 |
外科学 | 4951篇 |
综合类 | 235篇 |
一般理论 | 11篇 |
预防医学 | 1959篇 |
眼科学 | 625篇 |
药学 | 2685篇 |
中国医学 | 46篇 |
肿瘤学 | 2004篇 |
出版年
2022年 | 210篇 |
2021年 | 494篇 |
2020年 | 324篇 |
2019年 | 431篇 |
2018年 | 532篇 |
2017年 | 441篇 |
2016年 | 609篇 |
2015年 | 654篇 |
2014年 | 904篇 |
2013年 | 1201篇 |
2012年 | 1780篇 |
2011年 | 1855篇 |
2010年 | 1091篇 |
2009年 | 1160篇 |
2008年 | 1705篇 |
2007年 | 1854篇 |
2006年 | 1866篇 |
2005年 | 1817篇 |
2004年 | 1714篇 |
2003年 | 1643篇 |
2002年 | 1599篇 |
2001年 | 911篇 |
2000年 | 833篇 |
1999年 | 782篇 |
1998年 | 449篇 |
1997年 | 397篇 |
1996年 | 346篇 |
1995年 | 264篇 |
1994年 | 272篇 |
1993年 | 222篇 |
1992年 | 404篇 |
1991年 | 453篇 |
1990年 | 405篇 |
1989年 | 397篇 |
1988年 | 363篇 |
1987年 | 343篇 |
1986年 | 351篇 |
1985年 | 345篇 |
1984年 | 258篇 |
1983年 | 239篇 |
1980年 | 173篇 |
1979年 | 262篇 |
1978年 | 204篇 |
1977年 | 172篇 |
1976年 | 169篇 |
1975年 | 191篇 |
1974年 | 196篇 |
1973年 | 179篇 |
1972年 | 174篇 |
1930年 | 173篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献
3.
4.
5.
6.
Die Anaesthesiologie - Das Management des schwierigen Atemwegs ist eine präklinische Schlüsselqualifikation. Für Notärzte mit hohem Erfahrungsgrad im Atemwegsmanagement sind... 相似文献
7.
8.
9.
Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. 总被引:1,自引:0,他引:1
Samer Ezziddin Timur Logvinski Charlotte Yong-Hing Hojjat Ahmadzadehfar Hans-Peter Fischer Holger Palmedo Jan Bucerius Michael J Reinhardt Hans-Jürgen Biersack 《Journal of nuclear medicine》2006,47(2):223-233
Radiolabeled octreotide analogs (Oct) and metaiodobenzylguanidine (MIBG) offer 2 different approaches for imaging and targeting metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET). Despite successful establishment of the revised World Health Organization (WHO) classification, which distinguishes between low- and high-grade malignant GEP-NET, there is a lack of scintigraphic studies comparing uptake behavior on the basis of this categorization. This study aims to define predisposing factors of tracer uptake for both imaging principles implementing the updated tumor criteria of the current WHO classification. METHODS: Fifty-seven consecutive patients with histologically confirmed metastatic GEP-NET evaluated with both 111In-pentetreotide and 123I/131I-MIBG scintigraphy were included in this study. Intensity of tracer uptake was graded according to the different metastatic regions. Patients were classified as overall positive when avid uptake in the clinically relevant tumor lesions was present. Correlation was tested between the proportion of positive patients and tumor origin, function, and malignancy. RESULTS: Overall, 52 patients (91.2%) were Oct positive and 28 patients (49.1%) were MIBG positive. The proportion of tracer-positive patients was significantly higher (P < 0.05) in low-grade malignant tumors for both tracers and in functioning as well as in gastroenteral NET for MIBG. Five patients were negative for both tracers. None of the Oct-negative patients proved to be MIBG positive. CONCLUSION: Oct affinity is observed with high frequency throughout the subgroups of metastatic GEP-NET, whereas corresponding MIBG uptake is overall less prevalent and more group dependent. Tumor differentiation significantly impacts both Oct and MIBG uptake, whereas functionality predisposes only for MIBG accumulation. Though clearly inferior to Oct-based radioimaging in most GEP-NET, MIBG achieves a remarkable rate of radioligand accumulation in functioning midgut enterochromaffin cell metastases (>80% of patients positive). These results may have implications for patient management and potentially for selection and performance of targeted therapy. 相似文献
10.
Joachim Fensterle 《Journal der Deutschen Dermatologischen Gesellschaft》2006,4(3):205-216
Many cellular signaling pathways are involved in the development of cancer. Depending on the tumor entity, the nature as well as the mode of activation can differ. Some signaling pathways frequently show changes as all tumor cells have to fulfill some basic requirements such as independence from growth factors or insensitivity against apoptosis. In this review, the possibilities of a tumor to manipulate signaling pathways to reach these goals are exemplified based on an archetypical melanoma cell. In addition, new therapeutic options based on the knowledge of signaling pathways will be discussed. 相似文献